Beta Bionics, Inc.
NASDAQ:BBNXMedical - Equipment & Services
+$0.42 today
- Market cap
- $644.70M
- Beta
- 3.39
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.50
Volume 1.38M
Average 0.99M
BBNX Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Beta Bionics, Inc.NASDAQ: BBNX
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue grows, but more slowly than its trailing trend
Q1 FY2026 cost of revenue of $11.19M rose 29.1% year over year, behind the +46.8% change in trailing-twelve-month cost of revenue. Sequentially, it fell 15.1% from the prior quarter.
Context
- Cost of revenue amounted to 44.6% of revenue in FY2025, down 0.3 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +29.1% toward the trailing-twelve-month pace of +46.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 44.71M USD
- Year-over-year change
- +52.9%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 44.71M | +52.9% |
| FY2024 | 2024-12-31 | 29.24M | +414.1% |
| FY2023 | 2023-12-31 | 5.69M | — |
| FY2022 | 2022-12-31 | 0 | — |
Cost of Revenue vs competitors
How BBNX compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +46.8% is the highest of 7, against a peer median of +10.0%.
- Cost of revenue amounts to 42.8% of revenue for BBNX, versus a peer median of 33.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 63.75B DKK | +27.3% | +27.4% | 19.4% | |
| LTM Jun 2026 | $1.86B USD | +5.2% | +21.9% | 37.5% | |
MMEDMiniMed Group, Inc. Common Stock | LTM Jul 2026 | $1.49B USD | — | +14.9% | 46.2% |
| LTM Jun 2026 | $883.1M USD | +27.9% | +15.4% | 28.9% | |
| LTM Mar 2026 | $463.14M USD | -21.4% | +7.6% | 45.1% | |
| LTM Mar 2026 | $86.73M USD | +14.8% | +2.1% | 24.0% | |
| LTM Mar 2026 | $47.24M USD | +46.8% | — | 42.8% | |
| LTM Mar 2026 | $31K USD | -98.5% | — | — | |
| Peer median (excluding BBNX) | — | +10.0% | +15.2% | 33.2% | |
Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 179K | 12M | 65.12M | 100.25M |
| Cost of Revenue | 0 | 5.69M | 29.24M | 44.71M |
| Gross Profit | 179K | 6.31M | 35.89M | 55.54M |
| Gross Margin | 100.0% | 52.6% | 55.1% | 55.4% |
| Research & Development | 31.43M | 17.94M | 26.18M | 34.79M |
| Selling, General & Admin | 33.5M | 24.22M | 54.96M | 92.43M |
| Operating Expenses | 66.02M | 42.16M | 81.14M | 127.22M |
| Depreciation & Amortization | 1.35M | 1.23M | 1.15M | 2.88M |
| EBITDA | (63.4M) | (42.87M) | (53.61M) | (70.32M) |
| EBITDA Margin | -35418.4% | -357.4% | -82.3% | -70.1% |
| Operating Income | (65.84M) | (35.85M) | (45.25M) | (71.68M) |
| Operating Margin | -36784.4% | -298.9% | -69.5% | -71.5% |
| Interest Income | 196K | 1.78M | 3.91M | 10.93M |
| Interest Expense | 14K | 0 | 0 | 0 |
| Other Income / Expenses | 1.09M | (8.25M) | (9.51M) | (1.52M) |
| Income Before Tax | (64.75M) | (44.1M) | (54.76M) | (73.2M) |
| Pre-Tax Margin | -36173.7% | -367.6% | -84.1% | -73.0% |
| Income Tax Expense | 0 | 0 | 0 | 1K |
| Net Income | (64.75M) | (44.1M) | (54.76M) | (73.2M) |
| Net Margin | -36173.7% | -367.6% | -84.1% | -73.0% |
| EPS (Basic) | (12.96) | (8.31) | (8.60) | (1.81) |
| EPS (Diluted) | (12.96) | (8.31) | (8.60) | (1.81) |
| Weighted Avg Shares | 5M | 5.3M | 6.37M | 40.53M |
| Weighted Avg Shares (Diluted) | 5M | 5.3M | 6.37M | 40.53M |
Beta Bionics, Inc.
NASDAQ:BBNX
Intrinsic Alpha fair value
Locked
Current Price
$14.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.